Vanguard Capital Management
DNLI icon

Vanguard Capital Management’s Denali Therapeutics DNLI Stock Holding History

Vanguard Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161M Buy
6,275,729
+127,772
+2% +$2.63M ﹤0.01% 1273
2026
Q1 		$118M Buy
+6,147,957
New +$122M ﹤0.01% 1379

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Vanguard Capital Management's DNLI Position: Q2 2026 in Review

Vanguard Capital Management increased its Denali Therapeutics (DNLI) stake by 2.1% in Q2 2026, buying an estimated $2.63M and bringing the position to 6,275,729 shares worth $161M. The position accounts for ﹤0.01% of the portfolio, ranked #1273.

Vanguard Capital Management first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 290 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Vanguard Capital Management held 6,275,729 shares of Denali Therapeutics worth $161M as of Q2 2026.
  • Vanguard Capital Management bought 127,772 Denali Therapeutics shares in Q2 2026, an estimated $2.63M.
  • Denali Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1273 holding.
  • Vanguard Capital Management first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 290 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.